PBT swung NZ$483.7m into loss as portfolio revalued sharply lower

What changed

Revenue (investment income) fell 9.4% to NZ$54.3m from NZ$59.9m, a manageable decline in its own right. The headline, however, is a NZ$483.7m swing in profit before tax, from +NZ$50.9m to −NZ$432.7m, with NPAT moving from +NZ$68.2m to −NZ$442.4m. Operating cash flow almost halved to NZ$27.5m from NZ$51.5m. Total assets and equity, which move together on this balance sheet, both contracted 18.9% to NZ$2.1b, consistent with a portfolio revaluation event. Gross borrowings rose to NZ$150.6m from NZ$100.0m, and cash climbed to NZ$125.9m from NZ$85.2m, so net debt weakened modestly to roughly NZ$24.7m. The final dividend was cut to 2.80p from 14.00p per share, and the full-year ordinary dividend dropped to 3.80p from 19.00p (the prior year also carried a separate 2.00p special versus 10.00p the year before).

What matters

• The PBT collapse is a revaluation event, not an operating one. Income receipts fell only 9.4%, yet PBT fell NZ$483.7m. With equity and total assets falling in lockstep by NZ$490.9m, the mechanism is mark-to-market losses on the investment portfolio, which dominate the income statement once realised and unrealised gains/losses are included.
• Tax is not the distortion. The effective tax rate moved from 23.2% to a small benefit of 2.2%, so the NPAT loss of NZ$442.4m tracks the PBT loss closely. PBT growth of −949.8% is the cleaner operating read, and it confirms that almost all of the damage sits above the tax line in portfolio revaluation.
• Balance-sheet direction turned. Borrowings rose by NZ$50.6m even as the equity base shrank 18.9%, taking leverage modestly higher at exactly the point portfolio values fell. ROE moved to −21.1% from +2.6%.

Expectations

No quantified targets, guidance, or forward-work disclosures were supplied. The HY22 shape showed NZ$32.3m of revenue (59.6% of the full year) and a NZ$191.9m NPAT loss (43.4% of the full-year loss), which implies second-half revenue of NZ$21.9m and a second-half NPAT loss of NZ$250.6m — i.e., the portfolio damage accelerated into the second half rather than stabilising. There is no stated target against which to benchmark, so the release supports only a backward-looking read: income generation held up reasonably, portfolio value did not.

Quality of result

The income-side result looks durable: dividend receipts fell in line with a difficult emerging-markets year but remained the dominant revenue driver. The NPAT loss, by contrast, is almost entirely non-cash portfolio revaluation and should not be read as recurring operating deterioration. Operating cash flow nonetheless fell 46.5% to NZ$27.5m, and cash conversion visibly deteriorated: the first half generated NZ$23.4m of operating cash (84.8% of full-year OCF), implying only NZ$4.2m in H2. That flags a genuine weakening in cash receipts that is separate from the mark-to-market loss. On working capital, receivable days stretched to 113.9 from 93.3, which is consistent with slower income receipts rather than a collections problem. Cash at bank rose principally because borrowings were drawn, not because underlying cash generation improved.

Unresolved

• The split between realised and unrealised portfolio losses is not visible in the supplied extraction, and no EBITDA or adjusted earnings reconciliation was provided.
• Concentration by country, sector, or top holding is not disclosed, leaving the source of the revaluation loss unattributed.
• The rationale for increasing gross borrowings by NZ$50.6m during a drawdown year is not explained in the supplied excerpts.
• No management commentary on forward income, dividend policy beyond the proposed 3.80p ordinary, or discount/NAV per share is provided.

This briefing cannot assess NAV per share, discount to NAV, or the portfolio composition driving the revaluation, because those disclosures were not in the supplied data.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.